Trump Administration Expands Fertility Treatment Coverage
The Trump administration has announced a deal with EMD Serono to lower drug prices, as part of a larger effort to improve affordability for fertility services.
- Lowering drug prices through a deal with EMD Serono
- New benefits rules to encourage employers to offer in vitro fertilization coverage outside of health insurance
- A Food and Drug Administration priority review voucher for another fertility drug not currently available in the U.S.
EMD Serono is the third drugmaker to strike a deal with the president, following recent announcements from Pfizer and AstraZeneca.
The administration's plan aims to expand coverage and improve affordability for fertility services.
Author's summary: Trump administration expands fertility treatment coverage.